Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090102 · ClinicalTrials.gov registry record · Phase 4
Mesalamine to Reduce T Cell Activation in HIV Infection
A Phase 4 study of HIV Infections and Sexually Transmitted Diseases, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01090102 is a Phase 4 study of HIV Infections and Sexually Transmitted Diseases that has completed, run by University of California, San Francisco. The registered enrollment target is 33 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01090102, a Phase 4 study of HIV Infections and Sexually Transmitted Diseases, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better recovery of the immune system. The study hypothesis is that decreasing inflammation directly in the gut may decrease both of these potential causes of chronic inflammation, potentially resulting in an immunologic benefit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mesalamine (5-aminosalicylic acid, Apriso)
Study Locations (1)
California
- University of California, San Francisco-San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090102
The ClinicalTrials.gov registry entry for NCT01090102 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01090102 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01090102 about?
NCT01090102 is a clinical study titled "Mesalamine to Reduce T Cell Activation in HIV Infection". The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better recovery of the immune system. The study hypothesis is that decreasing inf...
What is the current status of trial NCT01090102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2010-06. Estimated completion is 2012-12.
What conditions does trial NCT01090102 study?
This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Acquired Immunodeficiency Syndrome, Lentivirus Infections.
What interventions are being tested in trial NCT01090102?
The interventions under investigation include: Placebo (DRUG), Mesalamine (5-aminosalicylic acid, Apriso) (DRUG).
Who is sponsoring clinical trial NCT01090102?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01090102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.